Please ensure Javascript is enabled for purposes of website accessibility

Why Opko Health Stock Stumbled in November

By George Budwell - Dec 10, 2017 at 9:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Opko's anemic third-quarter earnings release caused investors to hit the exits last month.

What happened

Shares of Opko Health (OPK 3.95%) had another poor showing in November, with its stock shedding a whopping 19.5% of its value last month, according to data from S&P Global Market Intelligence. Opko's shares have now lost a stunning 43.4% of their value so far this year. 

Opko's chronic woes stem mainly from the poor commercial performance of its two core value drivers: prostate cancer test 4K Score and the chronic kidney disease drug Rayaldee. In fact, these two key products were a major reason why Opko whiffed on third-quarter revenue by a worrisome 17.5% -- compared to Wall Street's consensus estimate -- last month. 

Chalkboard chart illustrating a downward trend.

Image source: Getty Images.

So what

Despite the sizable commercial opportunities for both 4K Score and Rayaldee, Opko simply hasn't been able to deliver on its promise to shareholders to become a cash-flow positive, growth-oriented company. As a result, Opko's stock has attracted a significant number of short-sellers this year, as evidenced by its short interest sitting at an unsightly 18.8% of the float at last count. In other words, investor sentiment is overwhelmingly negative toward Opko right now.  

Now what

Perhaps the bigger problem is that Opko arguably lacks a surefire franchise-level drug in its clinical portfolio. As a result, Opko may need to make an acquisition or cut a licensing deal in order to bring in new blood, so to speak. Unfortunately, Opko appears to be throwing good money after bad by deciding to plow even more cash into the commercialization of 4K Score and Rayaldee.

Making matters worse, Opko is staring down a possible cash crunch in 2018. The company exited the most recent quarter with only $100.4 million in cash and equivalents, with an average quarterly burn rate of $15.97 million over the past 12 months. So while this beaten-down biotech stock might look like a compelling bargain based on its rock bottom price-to-sales ratio of 2.56, Opko is facing a number of financial and commercial headwinds that it might not be able to overcome at the end of the day. And that's why investors may want to stick to the sidelines with this falling knife right now. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
$2.63 (3.95%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.